Navigation Links
Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO

ST. PAUL, Minn., Oct. 28 /PRNewswire/ -- M.B.A. students at Columbia University today heard Prime Therapeutics President and CEO Eric Elliott speak about the history and future of pharmacy benefit management (PBMs). Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members.

In a speech titled, "Pharmaceutical Management: Past, Present and Future," Elliott provided an overview of the emergence of pharmacy and PBMs and what the industry should expect in the coming years. Delivered to an audience of graduate students in Columbia's well-known program on public health policy, Elliott's presentation on pharmacy benefit management was part of a series of health system lectures.

Elliott shared several compelling statistics to highlight the impact of pharmaceutical development and how they have permanently altered the health and health care of Americans:

  • Almost half of the increase in life expectancy achieved over the past 15 years in the industrialized world can be attributed to new drugs.
  • In the United States alone, the economic gains from medical innovation are estimated at more than $500 billion per year.

Elliott discussed how PBMs leverage a larger number of members to manage prices, provide less costly medications for patients, and provide greater value for plan sponsors. Elliott also touched on research that found that e-prescribing will help prevent 3.5 million harmful medication errors, and save the federal government $22 billion in drug and medical costs over the next 10 years.

"PBMs have pioneered the use of e-prescribing technology, which provides physicians with clinical and cost information on prescription options, allowing them to better counsel consumers on which medications will be the safest and most affordable choices," said Elliott.

Elliott also discussed how mail service provides lower costs and greater convenience for members and plan sponsors, and the significant opportunity that still remains to save on drug costs through greater use of generic medications.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members.

Providing pharmacy benefit services nationwide to nearly 17 million covered lives*, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at

*As of January 1, 2011

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
4. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
5. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
6. Partners with Columbia Medical Associates to Bring Affordable Healthcare to Washington State
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
11. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 Oramed Pharmaceuticals ... focused on the development of oral drug delivery systems, ... agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies ... oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed at ...
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... Stress, anxiety, illness, infection or even a need for eyeglasses can sometimes ... MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, Florida, said ... , “Bad headaches that don’t go away, that don’t have any other reason, ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... the driverless vehicle experience this summer, ushering in a new era of publicly ... driverless and electric shuttle, will continue to offer guests an up-close look at ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals with political issues ... it a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s ... more than anyone wants to admit when it comes to how people are viewed ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... course in Dallas, TX, on January 29 and 30, 2016. The course welcomes ... functions of their practices, to learn how to better succeed in the modern ...
(Date:11/30/2015)... ... 2015 , ... A novel class of antimicrobials that inhibits ... fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according ... analogs that target the functions of SecA, a central part of the general ...
Breaking Medicine News(10 mins):